Self Administration of High Viscosity Drugs
|発行||Greystone Research Associates||商品コード||345525|
|高粘度薬液の自己投与 Self Administration of High Viscosity Drugs|
|出版日: 2015年11月24日||ページ情報: 英文||
Devices, Therapies, Players, Strategies and Forecasts
Formulations that Push the Device Envelope
Growth in biological drugs has been driven by advances in biotechnology and host-vector engineering - advances that have led to a steady stream of biologics for a number of ailments and conditions. These powerful drugs come with a high cost-per-dose and the risk of significant side effects - factors that place an elevated emphasis on administration efficiency, safety and reliability. Many drugs in this class are characterized by physical properties and sensitivities that challenge the drug commercialization ecosystem. For example, monoclonal antibodies, perhaps the most significant category in terms of therapeutic and commercial importance, typically possess viscosities that are well above the normal limits of subcutaneous injection techniques. Drug developers and device designers are increasingly working in collaboration to address the goal of patient self-administration for biological injectables.
The value we provide to our clients and subscribers is best illustrated by our ability to consistently provide strategic direction and market knowledge that contributes to their tactical and strategic decision process.
As technology and products evolve, the level of precision in management decisions required to enable effective company performance is increasing. Such precision cannot be achieved without timely and accurate data about the company's macroscopic operating environment. The information that you and your management team require to execute your business and market strategies is unique to your organization and business model. This is why - in addition to the multi-client reports you will find on our site - we offer client-specific research services that start with customer-defined needs and culminate in assessments and analysis that answer the questions that represent risk to your business strategy. To discuss Greystone's Customer Defined Research services, we invite you to contact us.
A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.
'Most biological products are stored at 2 to 8°C. To avoid injection pain, an injectable/infusible drug is typically equilibrated to room temperature prior injection. The effect of temperature on viscosity is non-negligible and has to be factored into any product development program relying on a delivery method other than a traditional infusion set.' Table of Contents
Our reports are carefully researched and written to provide timely and insightful analysis of key factors and developments shaping the commercial marketplace. The focused nature of our publications is designed to allow readers to identify emerging demand and growth opportunities in selected markets. Numerous charts, tables and graphs complement the text, with evaluations and assessments of current and probable future market developments, technology issues and business factors - information necessary to compete effectively in the global marketplace.